While discussing Amarin, will the company find a partner to help launch Vascepa, or perhaps a buyer?

New drug launches to watch in the last four months of 2012: Medivation's Xtandi, Ironwood Pharmaceuticals' ( IRWD) Linzess, Onyx Pharma's ( ONXX) Kyprolis and Vivus' ( VVUS) Qsymia.

I can't mention Vivus and ignore Arena Pharmaceuticals ( ARNA), which is expected to receive DEA scheduling for Belviq before the end of the year so that the obesity drug can be launched early in 2013.

Will Peregrine Pharmaceuticals ( PPHM) sign a partner before starting the bavituximab phase III lung cancer study at year's end, as promised?

Same goes for YM BioSciences ( YMI): Where is the promised partner to co-develop the myelobfibrosis drug CYT387?

Can Idenix Pharmaceuticals ( IDIX) gather enough safety data to convince FDA to lift the clinical hold on its hepatitis C drugs? Will Achillion Pharmaceuticals ( ACHN), which like Idenix is seeking partners or buyers for its hepatitis C drugs, finally change its Facebook status to "In a Relationship?"

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)